In Vivo Structure Activity Relationship Study of Dorsomorphin Analogs Identifies Selective VEGF and BMP Inhibitors

Jijun Hao[1], **Joshua N. Ho**[1], **Jana A. Lewis**[2], **Kaleh A. Karim**[1], **R. Nathan Daniels**[3], **Patrick R. Gentry**[2,4], **Corey R. Hopkins**[2,4], **Craig W. Lindsley**[2,3,4,5], and **Charles C. Hong**[1,2,5,6]

[1] Division of Cardiovascular Medicine, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN 37232

[2] Department of Pharmacology, Vanderbilt University School of Medicine, Nashville, TN 37232

[3] Department of Chemistry, Vanderbilt University School of Medicine, Nashville, TN 37232

[4] Vanderbilt Program in Drug Discovery, Vanderbilt University School of Medicine, Nashville, TN 37232

[5] Vanderbilt Institute of Chemical Biology, Vanderbilt University School of Medicine, Nashville, TN 37232

[6] Research Medicine, Veterans Administration TVHS, Nashville, TN 37212

Abstract

The therapeutic potential of small molecule signaling inhibitors is often limited by off-target effects. Recently, in a screen for compounds that perturb zebrafish embryonic dorsoventral axis, we identified dorsomorphin, the first selective inhibitor of bone morphogenetic protein (BMP) signaling. Here we show that dorsomorphin has significant "off-target" effects against the VEGF (vascular endothelial growth factor) type-2 receptor (Flk1/KDR) and disrupts zebrafish angiogenesis. Since both BMP and VEGF signals are known to be involved in vascular development, we sought to determine whether dorsomorphin's anti-angiogenic effects are due to its impact on the BMP or VEGF signals through the development of analogs that target BMP but not VEGF signaling, and vise versa. In a *s*tructure activity relationship (SAR) study of dorsomorphin analogs based primarily on their effects on live zebrafish embryos, we identified highly selective and potent BMP inhibitors as well as selective VEGF inhibitors. One of the BMP inhibitors, DMH1, which exclusively targets the BMP, but not VEGF, pathway, dorsalized the embryonic axis without disrupting angiogenic process, demonstrating that BMP signaling was not involved in angiogenic process. This is one of the first full-scale SAR study performed in vertebrates, and demonstrates the potential of zebrafish as an attractive complementary platform for drug development that incorporates an assessment of *in vivo* bioactivity and selectivity in the context of a living organism.

Corresponding Author: Charles C. Hong (charles.c.hong@vanderbilt.edu), Division of Cardiovascular Medicine, Vanderbilt University School of Medicine, 2220 Pierce Ave., 383 PRB, Nashville, TN 37232, (615) 936-7032 (Ph), (615) 936-1872 (F).

Introduction

With advances in high-throughput screening capabilities, it is not difficult to identify compounds that target a particular protein or pathway. Rather, a greater challenge lies in identifying selective modulators and improving pharmaceutical, or ADMET (absorption, distribution, metabolism, excretion and toxicity), properties of lead compounds (1). In the traditional approach to pharmaceutical development, the initial efforts at lead optimization are focused on identifying structural analogs with the highest potency against a therapeutic target in *in vitro* assays. However, when the subsequent *in vivo* results clash with the predictions based on *in vitro* tests, it is difficult to determine whether such "failures" result from flawed biological underpinnings or compounds' intrinsic deficiencies, such as poor target selectivity or suboptimal *in vivo* bioavailability.

In principal, these pitfalls can be circumvented with the use of the *in vivo* zebrafish model early in the lead optimization phase. Rapid external development, transparency, and high fecundity make zebrafish ideal for large-scale *in vivo* characterization of bioactive small molecules (2–5). Since embryonic cells are capable of integrating multiple signaling pathways to trigger precise developmental outputs, a small molecule that selectively targets a signaling pathway involved in embryonic patterning will phenocopy genetic mutations in that pathway whereas nonspecific compounds will cause early embryonic lethality or nonspecific developmental delay. In addition, since drug exposure in embryos occurs by passive diffusion, the *in vivo* assessment takes into account compounds' intrinsic physiochemical properties, such as the octanol-water partition coefficient (commonly referred to as log P), a major determinant of drug-likeness and bioactivity of a small molecule (6). As a proof-of-principle, we identified dorsomorphin (Figure 1a), the first selective small molecule inhibitor of BMP signaling, based on its ability to phenocopy the dorsoventral (DV) pattern defects seen in the BMP pathway mutants (Figure 1b)(7).

Dorsomorphin and its analog LDN-193189 have been used to direct differentiation of stem cells and to demonstrate the therapeutic potential of targeting BMP signals for anemia and hyperossification syndromes (7–9). In particular, the discovery of dorsomorphin has immediate therapeutic implications for a debilitating heretofore incurable condition known as fibrodysplasia ossificans progressiva, which has recently been shown to be caused by activating mutations in ALK2 (ACVR1), a BMP type-I receptor (10–12).

However, enthusiasm regarding their utility and therapeutic potential is tempered by the fact that dorsomorphin had significant "off-target" effects, including AMPK inhibition (13). Since AMPK plays a central role in energy metabolism and is known to have beneficial cardiovascular and antitumor effects, inhibiting AMPK has potential to cause cardiotoxicity and promote tumorigenesis (14–16). Here we show that dorsomorphin also had significant inhibitory activity against the VEGF signaling, and caused a significant defect in the intersomitic vessel (ISV) formation, an angiogenic process known to require signaling by the VEGF type-II receptor (also known as Vegfr2/Kdr/Flk1)(17–20). However, because BMP signaling is also known to be involved in angiogenesis (21,22), it was possible that dorsomorphin treatment revealed a novel role of the BMP signal in ISV formation.

To distinguish between these possibilities and to generate additional potent and specific BMP and VEGF inhibitors, we undertook a large-scale *in vivo* SAR study of dorsomorphin analogs based on their effects on zebrafish embryos. We synthesized 63 distinct compounds using the parallel library synthesis approach and tested them in zebrafish embryos to identify highly selective and potent inhibitors of BMP as well as VEGF signaling. One of the analogs, DMH1, which exclusively targets the BMP, but not VEGF, signaling, dorsalized the embryonic axis

without disrupting ISV formation, demonstrating that BMP signaling is not required for zebrafish ISV formation.

Results and Discussion

During the course of characterizing the effects of dorsomorphin (Figure 1a) in zebrafish embryos, we found that it consistently caused significant defects in the ISV formation (Figure 1b), an angiogenic process known to require signaling by the VEGF type-II receptors (Kdr/Flk1) (23). To examine in detail dorsomorphin's effects on ISV formation, the *Tg(fli:1a:EGFP) y1* transgenic embryos expressing GFP under the control of an endothelial-specific promoter (24) were treated with various concentrations (0.1 to 100 μM) of dorsomorphin starting at 12 hours post fertilization (12-hpf). Because this stage follows the establishment of dorsoventral (DV) axis, this analysis focused only on dorsomorphin's effects on angiogenesis. After dorsomorphin treatment, ISV was visualized in live 48-hpf. In this *in vivo* angiogenesis model, dorsomorphin completely inhibited ISV formation at 10 μM (Figure 1b). At 5 μM, roughly 50% of the ISV were severely shortened or eliminated (dorsomorphin's EC50, effective concentration affecting 50% of ISVs, was therefore 5 μM; Table 1).

In cultured bovine aortic endothelial cells, dorsomorphin inhibited the VEGF-stimulated Flk1 phosphorylation in a dose-dependent manner (Figure 1c), demonstrating that dorsomorphin was a potent VEGF signal inhibitor. Nevertheless, since BMP signaling is also known to be involved in angiogenesis (21, 22), it was formally possible that the dorsomorphin's effects on the zebrafish vasculature revealed a novel role of the BMP signal in ISV formation. To test this, we sought to develop small molecules that specifically inhibited the BMP, but not the VEGF, signaling.

To generate additional potent and specific BMP inhibitors, we synthesized a number of molecules centered around the 3,6-disubstituted pyrazolo[1,5-*a*]pyrimidine core of dorsomorphin (Figure 1d; Figure S1; Tables S1, S2). Our effort was concentrated on varying two aspects of the dorsomorphin structure: the R_1 group (C-3 of the core structure) and the R_2 group (4-phenyl group on the C-6 of the core structure) (Figure 1d; Tables S1, S2)(25). The parallel library synthesis, as detailed in supplementary methods, led to the synthesis and isolation of 63 distinct compounds (Tables S1, S2).

Rather than the traditional approach of identifying structural analogs with the highest potency against BMP signaling in *in vitro* assays, the lead optimization effort was driven by the compounds' effects on live zebrafish embryos (Figure 2). *In vivo* effective concentrations (ECs) and relative selectivities against BMP signaling were assessed after administering the compounds at 3-hour post fertilization (hpf). Because this stage represents a key temporal landmark in zebrafish development when multiple cell signaling pathways fashion the initial embryonic pattern, nonselective inhibitors will cause early lethality, or nonspecific developmental defects, whereas the effects of selective BMP inhibitors will be limited to dorsalization of the embryonic axis. Of the initial set of 21 dorsomorphin analogs involving the modifications in the 6-position of the pyrazolo[1,5-*a*]pyrimidine backbone, 9 caused dorsalization without any associated early lethality, 7 caused early lethality, and 5 had no visible effect (Table S1). Among the 9 dorsalizing compounds, those with the lower effective concentrations (ECs) were deemed to have greater anti-BMP potency *in vivo*. In this *in vivo* selectivity assessment, both dorsomorphin and the previously reported analog LDN-193189 (9) caused substantial early lethality at 20 μM, suggesting significant off-target effects (Table 1).

Next, we examined the effects of the initial set of analogs and LDN-193189 on ISV formation by administering the compounds at 12-hpf and visualizing the ISV in live 48-hpf *Tg(fli:*

1a:EGFP)y1 embryos. When the compounds were added at this stage, none caused gross morphologic defects, or lethality within 24 hours of administration. In this analysis of *in vivo* angiogenesis, LDN-193189 significantly inhibited ISV formation at 20 μM (Table 1). Of the initial 21 analogs, 7 had no effect on ISV formation (Table S1). Of these 7, two (92Y and 6L1) affected DV axis, but only at high concentrations, indicating poor bioactivity (Table S1). The remaining five had no detectable *in vivo* activity, affecting neither ISV formation nor DV axis. Interestingly, included in this "inactive" group was 6LP, which was previously shown to have significant *in vitro* activity against KDR (IC50, concentration causing 50% inhibition, of 37nM)(26) (Suppl. Table 1). This discrepancy highlights the key fact that *in vitro* results do not necessarily predict *in vivo* bioactivity, presumably because they do not take into account a compound's solubility or bioavailability. The remaining 14 initial analogs affected both ISV formation and DV axis, although the individual impact on ISV formation and DV axis varied (Table S1). In summary, the modifications at the 6-position had only a modest impact on conferring the selectivity for DV axis. Thus, an additional round of derivatization was performed retaining several of the 6-position modifications (specifically analogs 6LE, 6K1 and 91E) that conferred enhanced bioactivity or relative selectivity and introducing modifications at the 3-position (Table 1; Table S2).

The modifications to the 3-position had a major impact on *in vivo* bioactivity and selectivity (Table S2). Specifically, replacement of the 4-pyridyl group at the 3-position with the 4-quinoline group (9,27) resulted in compounds with preferentially greater effect on DV axis over ISV formation (Table 1). Of particular interest were DMH1, DMH2 and DMH3, which did not have any detectible effect on ISV formation (Figure 3; Table 1; Figure 4A). The EC100s for dorsalization (effective concentration causing 100% of embryos to be severely dorsalized) were approximately 0.2, 0.1 and 1 μM for DMH1, DMH2 and DMH3, respectively, in comparison to 2 and 3 μM for dorsomorphin and LDN-193189, respectively (Table 1). DMH2 was the most potent dorsalizing compound but less selective than DMH1 and DHM3 since it caused nonspecific developmental effects at higher concentrations (Table 1).

Replacement of 4-pyridiyl group at the 3-position with the phenyl group resulted in compounds that preferentially effected ISV formation but not DV axis (Table 1). For example, DMH4, which had no discernable effect on DV axis, caused significant defects in the ISV and the subintestinal vessel (SIV) (Figure 3; Table 1; Figures 5a, 5b). Similar vascular defects have been noted in *kdra* mutants or in larvae treated with the Vegfr2 inhibitor SU5146 (19,20). DMH4's EC50 for ISV inhibition (effective concentration causing loss of 50% of ISVs) was 1 μM, compared to 5 μM for dorsomorphin (Table 1).

Next, we examined the effects of DMH1, DMH2 and DMH3, the analogs exhibiting highest selectivity for DV patterning, in a number of *in vitro* assays. In a BMP-responsive luciferase reporter assay (28), the IC50s for DMH1, DMH2 and DMH3 were found to be approximately 100 nM, 20 nM, and 7 nM, respectively (Figure 4b; Figure S2). In addition, *in vitro* assays using the purified human BMP type-I receptor ALK2 (activin receptor like kinase-2) confirmed that DMH1, DMH2 and DMH3 were direct inhibitors of ALK2 (IC50 of 107.9 nM, 42.8 nM, and 26.7 nM, respectively) (Table 2).

Consistent with their minimal effect on ISV formation, *in vitro* assays using the purified human KDR demonstrated that DMH1, DMH2, and DMH3 had greatly diminished KDR activity in comparison to dorsomorphin and LDN-193189 (IC50 of >30 μM, 2.4 μM, 2μM versus 25.1 nM and 214.7 nM, respectively; Table 2). Additional *in vitro* testing with the purified TGFβ Receptor ALK5, the AMPK, and the Platelet-Derived Growth Factor Receptor-β (PDGFRβ) demonstrated that DMH1, DMH2 and DMH3 each had substantially higher IC50 for all of these targets than LDN-193189 did (Table 2). Remarkably, DMH1 appeared to be very specific for ALK2 without any detectable inhibition of KDR, ALK5, AMPK, and PDGFRβ (Table 2).

Importantly, the lack of ISV effects by DMH1, an exquisitely selective BMP inhibitor without any detectable KDR activity, demonstrates that BMP signal, at least which which is mediated by Smad1/5/8, is not required for zebrafish ISV formation.

On Western blots, DMH1, like dorsomorphin (7), selectively inhibited the BMP-induced Smad1/5/8 activation (Figure 4c), but not the p38/MAP kinase signaling (Figure 4c) or the Activin A-induced Smad2 activation (Figure 4d). Consistent with the *in vitro* kinase assay result, DHM1 had no effect on VEGF-induced Flk1 phosphorylation (Figure 4e). To determine whether DMH1 had subtype selectivity, we transfected the BMP signal reporter cells (28) with the constitutively active (ca) forms of the BMP type-I receptors ALK2, ALK3, and ALK6 (29), and examined DMH1's effect on BMP-responsive luciferase activity. In this assay, DMH1 effectively inhibited signaling by caALK2 and caALK3 (IC50 for both significantly less than 0.5 μM), but had negligible effect on signaling by caALK6 (Figure S3). These results suggest that additional modifications may lead to further refinements in the subtype selectivity. From the clinical perspective, a more selective small molecule that targets just the ALK2, but ALK3 or ALK6, would be desirable as a potential treatment for fibrodysplasia ossificans progressiva (10,12).

In the above *in vivo* SAR study, DMH4 had no discernable effect on DV (Figure 5b), but caused significant defects in the ISV and SIV formation (Figure 5a). Additionally, 1 μM DMH4 effectively blocked angiogenesis in a Matrigel angiogenesis assay using human umbilical vein endothelial cells (Figure 5c). These anti-angiogenic effects of DMH4 were not mediated through BMP inhibition since, in *in vitro* BMP reporter and purified ALK2 kinase assays, DMH4 did not inhibit BMP signaling at such low concentrations (Figure 5d; Table 2). Rather, DMH4 effectively blocked VEGF-stimulated phosphorylation of both Flk1 and the downstream mediator Akt in a dose dependent manner (Figures 5e, 5f). Furthermore, in an *in vitro* assay using the purified human Vegfr2 (KDR), DMH4 was found to be a direct inhibitor with IC50 of 161 nM (Table 2). Interestingly, in our *in vivo* angiogenesis analysis, the commonly utilized KDR inhibitor SU5146 (Semaxanib) (30), which was originally developed as an antiangiogenesis therapy, was less potent than DMH4 and not selective (Table 1).

For several compounds, the IC50s based on the *in vitro* KDR kinase assays differed dramatically from the EC50s based on their effects on ISV formation (Tables 1, 2). For example, dorsomorphin, LDN-193189 and 6LP were potent KDR inhibitors *in vitro* (IC50s 25.1, 214.7 and 37nM, respectively), yet all were relatively poor angiogenesis inhibitors in embryos (EC50s 5 μM, 20 μM and >50 μM, respectively; Tables 1, 2). Such IC50-EC50 disparities may reflect suboptimal bioavailabilities of these compounds in later stage (~24-hpf) embryos. In summary, the zebrafish proved to be an effective platform for the rapid identification of highly selective VEGF inhibitors with excellent *in vivo* potencies and favorable physiochemical properties.

Here, we utilized zebrafish to conduct the first full-scale *in vivo* SAR study in a vertebrate model to simultaneously identify selective small molecule inhibitors of BMP and VEGF pathways, both of which are recognized as important therapeutic targets. Our analyses indicate that modification of the 3-position of the pyrazolo[1,5-*a*]pyrimidine backbone of dorsomorphin plays a critical role in determining KDR versus BMP receptor selectivity. Using this approach, we identified a potent and selective KDR inhibitor (DMH4), as well as several highly selective BMP type-I receptor inhibitors, including DMH1, which does not target any of the related signaling pathways tested. Exquisitely selective BMP inhibitors, such as DMH1, which do not affect AMPK are preferred for further development as potential therapeutic leads since they should have reduced potential for cardiotoxicity and other undesired effects than the compounds that inhibit AMPK. Lastly, using DMH1, we demonstrated that BMP signaling is not required for angiogenesis in early zebrafish embryos.

The *in vivo* SAR's success in identifying potent and selective inhibitors of not only the BMP, but also VEGF, signaling demonstrates that the zebrafish provides an effective multi-dimensional approach to simultaneously interrogate multiple pathways on a whole organism scale. Moreover, since the *in vivo* SAR study assesses the compounds' bioactivities in live embryos, this approach is inherently likely to identify compounds having favorable physiochemical properties and excellent "drug-likeness." Thus, this approach is useful for avoiding the pitfall of pursuing "dead end" leads, such as 6LP, which have excellent *in vitro* activity yet have poor *in vivo* bioactivity. The *in vivo* SAR study contrasts with the traditional *in vitro* assay-based SAR studies that focus on identifying analogs with the highest potency. Such a "linear approach," which does not take into account selectivity and physicochemical properties until later in drug development, can lead to compounds that ultimately fail in preclinical animal models despite having a compelling biological rationale. In conclusion, we demonstrate that the zebrafish is an attractive complementary platform for pharmaceutical development that incorporates the assessment of a lead compound's *in vivo* bioactivity and selectivity earlier in the development process.

Methods

Zebrafish experiments

The wild-type embryos were treated with various concentrations (0.1 μM to 100 μM) of the compounds starting at 3-hpf to evaluate compounds' effects on the dorsoventral axis, and the *Tg(Fli:EGFP)y*1 (18,24) transgenic embryos were treated from 12-hpf to evaluate the effects on ISV formation. 20 embryos were treated per well condition. Treated embryos were manually dechorionated and observed at 24, 48 and 72-hpf.

Cells and cell culture

C2C12, C2C12BRA and Bovine aortic endothelial cells (BAEC) were cultured in DMEM supplemented with 10% FBS (Gibco) and 1% penicillin/streptomycin (Cellgro). Human umbilical vein endothelial cells (HUVEC) were grown in EGM-2 Bulletkit medium (Lonza). Both BAEC and HUVEC cell lines were cultured on 0.2% gelatin-coated dishes.

Endothelial tubule formation

1.5×10^4 HUVEC cells were plated on a 96 well micro-titer plate pre-coated with 50 μL ECMatrix™ (Millipore) and were treated with DMSO or DMH4. After 15hr incubation, tubular network formation was examined under an inverted light microscope.

Western blotting

For VEGF signaling, confluent BAEC cells were serum-starved for 18–24 hrs, and then treated with the compounds or DMSO for 30 min followed by 8 min incubation with 50ng/ml $VEGF_{165}$ (Alpha Diagnostics International, Inc). For Smad and P38 MAPK activation, confluent HEK293 cells were serum-starved and then treated with the compounds or DMSO for 30 min followed by 30 min incubation with BMP4 (50 ng/ml) or Activin-A (40 ng/ml). After stimulation, cells were then lysed in CelLytic-M cell lysis buffer (Sigma) supplemented with protease inhibitor cocktail (Sigma) and phosphatase inhibitor cocktail 2 (Sigma). Lysates were separated by SDS/PAGE and transferred onto PVDF membrane. The p-Flk1, p-Smad1/5/8, p-Smad2, p-AKT, p-P38MAPK, Flk1, AKT and alpha-tubulin were detected by Odyssey system (Li-Cor bioscience) after incubation with the appropriate primary and secondary antibodies. Primary antibodies include anti-rabbit p-Flk1(Santa Cruz, 1:200 dilution), anti-rabbit p-Smad1/5/8 (Cell Signaling Tech, 1:1000), anti-rabbit p-Smad2 (Cell Signaling Tech, 1:1000) and anti-mouse p-AKT (Cell Signaling Tech, 1:1000 dilution), anti-mouse p-P38MAPK (Cell Signaling Tech, 1:1000), anti-mouse Flk1 (Santa Cruz, 1:200

dilution), and anti-rabbit Akt (Cell signaling, 1:1000 dilution). The secondary antibodies include IRDye 680-conjugated goat anti-rabbit IgG (Li-Cor Bioscience, 1:5000 dilution) and IRDye 800CW-conjugated goat anti-mouse IgG (Li-Cor Bioscience, 1:5000 dilution).

BMP-responsive luciferase reporter assays

Stably transfected BMP-responsive C2C12BRA cells (containing the *Id1* promoter-firefly luciferase reporter; kind gift of D, Rifkin, NYU Medical Center(28)) were seeded in 96-well plates, and incubated overnight with the compounds and BMP4 (50 ng/ml). The cells were then lysed, and cell extracts were then subjected to the firefly luciferase assay using Steady-Glo luciferase assay kit (Promega). The results were normalized to cell titers, as measured using Cell Titer-Glo luminescence assay (Promega). For subtype analysis, C2C12BRA cells were transiently transfected with plasmids (0.1 μg) expressing constitutively active forms of the BMP type I receptors (caALK2, caALK3 or caALK6) using Lipofectamine kit (Invitrogen) in 96 well plates. 0.1 μg of pRL-TK Renilla luciferase (Promega) was used to control for transfection efficiency. Relative activity was quantified by the ratio of firefly to Renilla luciferase activities using the dual luciferase assay kit (Promega).

Kinase assay

All kinase assays were conducted by Reaction Biology Corp (Malvern, PA). In brief, compounds were tested at 10 concentrations by 3-fold serial dilutions starting at 30 μM, using nonspecific kinase inhibitor staurosporine as control. *In vitro* kinase reactions were carried out in the presence of 10 μM (^{33}P)γATP. Five kinases tested were the human BMP type-I receptor activin receptor-like kinase 2 (ALK-2/ACVR1), the human TGFβ type-I receptor activin receptor-like kinase 5 (Alk5/TGFβR1), the human VEGF type-II receptor (KDR/Flk-1/VEGFR2), the human AMP-activated protein kinase (AMPK/A1/B1/G1) and the human platelet-derived growth factor receptor-β (PDGFRβ).

Chemical synthesis

The synthetic chemistry effort was concentrated on varying two aspects of the 3,6-disubstituted pyrazolo[1,5-*a*]pyrimidine core of dorsomorphin (Figure S3): the R_1 group (C-3 of the core structure), and the R_2 group (4-phenyl group on the C-6 of the core structure). Based on the known synthetic methods available, we varied the R_1 (phenyl, 2-, 3-, and 4-pyridyl, 3-quinoline, 4-quinoline, 2-thiophene, and 2-thiazole) and R_2 (alkyl ethers). Our library synthesis was focused on common intermediates **3** and **7** which were synthesized via different pathways depending on the 3-aryl substitution required (Schemes S1, S2). For the phenyl and pyridyl derivatives, the synthesis started with the known 4-aryl-1*H*-pyrazol-5-amine **1**(31–33) which was reacted with malondialdehyde **2** which afforded the pyrazolo[1,5-*a*]pyrimidine core **3** (Scheme S1). Next, the methoxy group was deprotected and then the phenol was alkylated under basic conditions with a number of groups affording the final products **4** (Tables S1, S2) (31). For the other 3-heteroaryl substituted pyrazolo[1,5-*a*]pyrimidine compounds **7**, the commercially available 4-bromo-1*H*-pyrazol-5-amine **5** was reacted as above with malondialdehyde **2** which afforded the 3-bromo pyrazolo[1,5-*a*]pyrimidine core **6** (Scheme S2). Next, **6** underwent transition metal catalyzed cross coupling with either an appropriate boronic acid(34), or arylzinc bromide(35) to afford the desired **7**. Compound **7** was then reacted as above to yield the final targets **4** (Tables S1, S2). This reaction sequence was amenable to parallel library synthesis and utilizing this approach led to the synthesis and isolation of 63 distinct compounds. Detailed synthesis schemes are discussed in Supporting Information.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

References

1. MacCoss M, Baillie TA. Organic chemistry in drug discovery. Science 2004;303:1810–1813. [PubMed: 15031494]

2. Zon LI, Peterson RT. In vivo drug discovery in the zebrafish. Nat Rev Drug Discov 2005;4:35–44. [PubMed: 15688071]

3. Molina G, Vogt A, Bakan A, Dai W, Queiroz de Oliveira P, Znosko W, Smithgall TE, Bahar I, Lazo JS, Day BW, Tsang M. Zebrafish chemical screening reveals an inhibitor of Dusp6 that expands cardiac cell lineages. Nat Chem Biol 2009;5:680–687. [PubMed: 19578332]

4. MacRae CA, Peterson RT. Zebrafish-based small molecule discovery. Chem Biol 2003;10:901–908. [PubMed: 14583256]

5. Hong CC. Large-scale small-molecule screen using zebrafish embryos. Methods in molecular biology (Clifton, NJ) 2009;486:43–55.

6. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 2001;46:3–26. [PubMed: 11259830]

7. Yu PB, Hong CC, Sachidanandan C, Babitt JL, Deng DY, Hoyng SA, Lin HY, Bloch KD, Peterson RT. Dorsomorphin inhibits BMP signals required for embryogenesis and iron metabolism. Nat Chem Biol 2008;4:33–41. [PubMed: 18026094]

8. Hao J, Daleo MA, Murphy CK, Yu PB, Ho JN, Hu J, Peterson RT, Hatzopoulos AK, Hong CC. Dorsomorphin, a selective small molecule inhibitor of BMP signaling, promotes cardiomyogenesis in embryonic stem cells. PLoS ONE 2008;3:e2904. [PubMed: 18682835]

9. Yu PB, Deng DY, Lai CS, Hong CC, Cuny GD, Bouxsein ML, Hong DW, McManus PM, Katagiri T, Sachidanandan C, Kamiya N, Fukuda T, Mishina Y, Peterson RT, Bloch KD. BMP type I receptor inhibition reduces heterotopic [corrected] ossification. Nat Med 2008;14:1363–1369. [PubMed: 19029982]

10. Shen Q, Little SC, Xu M, Haupt J, Ast C, Katagiri T, Mundlos S, Seemann P, Kaplan FS, Mullins MC, Shore EM. The fibrodysplasia ossificans progressiva R206H ACVR1 mutation activates BMP-independent chondrogenesis and zebrafish embryo ventralization. J Clin Invest 2009;119:3462–3472. [PubMed: 19855136]

11. Kaplan FS, Xu M, Seemann P, Connor JM, Glaser DL, Carroll L, Delai P, Fastnacht-Urban E, Forman SJ, Gillessen-Kaesbach G, Hoover-Fong J, Koster B, Pauli RM, Reardon W, Zaidi SA, Zasloff M, Morhart R, Mundlos S, Groppe J, Shore EM. Classic and atypical fibrodysplasia ossificans progressiva (FOP) phenotypes are caused by mutations in the bone morphogenetic protein (BMP) type I receptor ACVR1. Hum Mutat 2009;30:379–390. [PubMed: 19085907]

12. Shore EM, Xu M, Feldman GJ, Fenstermacher DA, Cho TJ, Choi IH, Connor JM, Delai P, Glaser DL, LeMerrer M, Morhart R, Rogers JG, Smith R, Triffitt JT, Urtizberea JA, Zasloff M, Brown MA, Kaplan FS. A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva. Nat Genet 2006;38:525–527. [PubMed: 16642017]

13. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N, Musi N, Hirshman MF, Goodyear LJ, Moller DE. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001;108:1167–1174. [PubMed: 11602624]

14. Russell RR 3rd, Li J, Coven DL, Pypaert M, Zechner C, Palmeri M, Giordano FJ, Mu J, Birnbaum MJ, Young LH. AMP-activated protein kinase mediates ischemic glucose uptake and prevents postischemic cardiac dysfunction, apoptosis, and injury. J Clin Invest 2004;114:495–503. [PubMed: 15314686]

15. Sasaki H, Asanuma H, Fujita M, Takahama H, Wakeno M, Ito S, Ogai A, Asakura M, Kim J, Minamino T, Takashima S, Sanada S, Sugimachi M, Komamura K, Mochizuki N, Kitakaze M. Metformin prevents progression of heart failure in dogs: role of AMP-activated protein kinase. Circulation 2009;119:2568–2577. [PubMed: 19414638]

16. Vazquez-Martin A, Oliveras-Ferraros C, Lopez-Bonet E, Menendez JA. AMPK: Evidence for an energy-sensing cytokinetic tumor suppressor. Cell Cycle 2009;8

17. Bussmann J, Lawson N, Zon L, Schulte-Merker S. Zebrafish VEGF receptors: a guideline to nomenclature. PLoS genetics 2008;4:e1000064. [PubMed: 18516225]

18. Isogai S, Lawson ND, Torrealday S, Horiguchi M, Weinstein BM. Angiogenic network formation in the developing vertebrate trunk. Development (Cambridge, England) 2003;130:5281–5290.

19. Covassin LD, Villefranc JA, Kacergis MC, Weinstein BM, Lawson ND. Distinct genetic interactions between multiple Vegf receptors are required for development of different blood vessel types in zebrafish. Proc Natl Acad Sci U S A 2006;103:6554–6559. [PubMed: 16617120]

20. Habeck H, Odenthal J, Walderich B, Maischein H, Schulte-Merker S. Analysis of a zebrafish VEGF receptor mutant reveals specific disruption of angiogenesis. Curr Biol 2002;12:1405–1412. [PubMed: 12194822]

21. Heinke J, Wehofsits L, Zhou Q, Zoeller C, Baar KM, Helbing T, Laib A, Augustin H, Bode C, Patterson C, Moser M. BMPER is an endothelial cell regulator and controls bone morphogenetic protein-4-dependent angiogenesis. Circ Res 2008;103:804–812. [PubMed: 18787191]

22. Scharpfenecker M, van Dinther M, Liu Z, van Bezooijen RL, Zhao Q, Pukac L, Lowik CW, ten Dijke P. BMP-9 signals via ALK1 and inhibits bFGF-induced endothelial cell proliferation and VEGF-stimulated angiogenesis. Journal of cell science 2007;120:964–972. [PubMed: 17311849]

23. Fraley ME, Rubino RS, Hoffman WF, Hambaugh SR, Arrington KL, Hungate RW, Bilodeau MT, Tebben AJ, Rutledge RZ, Kendall RL, McFall RC, Huckle WR, Coll KE, Thomas KA. Optimization of a pyrazolo[1,5-a]pyrimidine class of KDR kinase inhibitors: improvements in physical properties enhance cellular activity and pharmacokinetics. Bioorg Med Chem Lett 2002;12:3537–3541. [PubMed: 12443771]

24. Lawson ND, Weinstein BM. In vivo imaging of embryonic vascular development using transgenic zebrafish. Dev Biol 2002;248:307–318. [PubMed: 12167406]

25. Daniels RN, Kim K, Lebois EP, Muchalski H, Hughes M, Lindsley CW. Microwave-assisted protocols for the expedited synthesis of pyrazolo[1,5-a] and [3,4-d]pyrimidines. Tetrahedron Letters 2008;49:305–310.

26. Fraley ME, Hoffman WF, Rubino RS, Hungate RW, Tebben AJ, Rutledge RZ, McFall RC, Huckle WR, Kendall RL, Coll KE, Thomas KA. Synthesis and initial SAR studies of 3,6-disubstituted pyrazolo[1,5-a]pyrimidines: a new class of KDR kinase inhibitors. Bioorg Med Chem Lett 2002;12:2767–2770. [PubMed: 12217372]

27. Cuny GD, Yu PB, Laha JK, Xing X, Liu JF, Lai CS, Deng DY, Sachidanandan C, Bloch KD, Peterson RT. Structure-activity relationship study of bone morphogenetic protein (BMP) signaling inhibitors. Bioorg Med Chem Lett 2008;18:4388–4392. [PubMed: 18621530]

28. Zilberberg L, ten Dijke P, Sakai LY, Rifkin DB. A rapid and sensitive bioassay to measure bone morphogenetic protein activity. BMC cell biology 2007;8:41. [PubMed: 17880711]

29. Fujii M, Takeda K, Imamura T, Aoki H, Sampath TK, Enomoto S, Kawabata M, Kato M, Ichijo H, Miyazono K. Roles of bone morphogenetic protein type I receptors and Smad proteins in osteoblast and chondroblast differentiation. Mol Biol Cell 1999;10:3801–3813. [PubMed: 10564272]

30. Fong TA, Shawver LK, Sun L, Tang C, App H, Powell TJ, Kim YH, Schreck R, Wang X, Risau W, Ullrich A, Hirth KP, McMahon G. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer research 1999;59:99–106. [PubMed: 9892193]

31. Daniels RN, Kim K, Lebois EP, Muchalski H, Hughes M, Lindsley CW. Microwave-assisted protocols for the expedited synthesis of pyrazolo[1,5-*a*] and [3,4-*d*]pyrimidines. Tetrahedron Lett 2008;49:305–310.

32. Fraley ME, Hoffman WF, Rubino RS, Hungate RW, Tebben AJ, Rutledge RZ, McFall RC, Huckle WR, Kendall RL, Coll KE, Thomas KA. Synthesis and initial SAR studies of 3,6-disubstituted

pyrazolo[1,5-*a*]pyrimidines: a new class of KDR kinase inhibitors. Bioorg Med Chem Lett 2002;12:2767–2770. [PubMed: 12217372]

33. Fraley ME, Rubino RS, Hoffman WF, Hambaugh SR, Arrington KL, Hungate RW, Bilodeau MT, Tebben AJ, Rutledge RZ, Kendall RL, McFall RC, Huckle WR, Coll KE, Thomas KA. Optimization of a pyrazolo[1,5-*a*]pyrimidine class of KDR kinase inhibitors: improvements in physical properties enhance cellular activity and pharmacokinetics. Bioorg Med Chem Lett 2002;12:3537–3541. [PubMed: 12443771]

34. Miyaura N, Suzuki A. Palladium-catalyzed cross-coupling reactions of organoboron compounds. Chem Rev 1995;95:2457–2483.

35. King AO, Okakadao N, E-i N. Highly general stereo-, regio-, and chemo-selective synthesis of terminal and internal conjugated enynes by the Pd-catalyzed reaction of alkynylzinc reagents with alkenyl halides. J Chem Soc Chem Comm 1977:683–684.

Figure 1. Dorsomorphin inhibits both BMP and VEGF signaling, and the pyrazolo[1,5-*a*] pyrimidine backbone of DM for derivatization

(a) Structure of dorsomorphin (DM). **(b)** 2 μM DM dorsalized zebrafish embryos when administered at 3 hours post fertilization (hpf), and 10 μM DM blocked intersomitic vessel (ISV) formation when administered at 12-hpf. Above, bright-field images treated embryos. Below, green fluorescence images of the *Tg(Fli:EGFP)y*1 transgenic embryos, which express GFP in the vasculature. Control embryos treated with DMSO are on left, and DM-treated embryos are on right. **(c)** DM suppressed VEGF-dependent Flk1 phosphorylation in a dose-dependent manner in bovine arterial endothelial cells (BAECs). **(d)** The pyrazolo[1,5-a] pyrimidine backbone of DM for derivatization involving modifications at the 3- and 6-positions (red circles).

Figure 2. Schema of zebrafish-based structure-activity relationship (SAR) study of DM analogs
To assess each analog's effect on dorsoventral (DV) axis, the wild-type embryos were exposed
to the compound (at concentration from 0.01 μM to 50 μM) starting at 3-hpf. To assess each
analog's effect on angiogenesis, the *Tg(Fli:EGFP)y*1 embryos were exposed to each compound
(from 0.01 μM to 50 μM) starting at 12-hpf. After 48 hrs, the compound-treated embryos were
manually scored for dorsalization of the DV axis (BMPR-I inhibition), vascular defects
(VEGFR-2 inhibition), and nonspecific toxicity or defects. The compounds which caused
dorsalization or blocked angiogenesis were considered for the subsequent round of analog
synthesis and testing.

Figure 3. Chemical Structures, IUPAC Nomenclatures and LC/MS analyses of DMH1, DMH2, DMH3 and DMH4

DMH1: 4-(6-(4-isopropoxyphenyl)pyrazolo[1,5-a]pyrimidin-3-yl)quinoline; >98% @ 214 nM, Rt = 2.48 min, m/z = 381.2 [M + H].

DMH2: 4-(2-(4-(3-(quinolin-4-yl)pyrazolo[1,5-*a*]pyrimidin-6-yl)phenoxy)ethyl)morpholine; >98% @ 214 nM, Rt = 0.72 min, m/z = 452.2 [M + H]

DMH3: *N,N*-dimethyl-3-(4-(3-(quinolin-4-yl)pyrazolo[1,5-*a*]pyrimidin-6-yl)phenoxy) propan-1-amine; >98% @ 214 nM, Rt = 0.76 min, m/z = 424.3 [M + H]

DMH4: 4-(2-(4-(3-phenylpyrazolo[1,5-*a*]pyrimidin-6-yl)phenoxy)ethyl)morpholine; >98% @ 214 nM, R_T = 0.89 min., m/z = 401.2 [M + H].

Figure 4. DMH1 is a potent and selective inhibitor of BMP signaling
(a) DMH1 (0.2 μM) caused severe dorsalization when the embryos were treated from 3-hpf (above), but it (100 μM) had no effect on ISV formation when the embryos were treated from 12-hpf (below, green fluorescence marks vascular endothelium). **(b)** DMH1 inhibited BMP signaling in a dose dependent manner in BMP-responsive luciferase reporter assay. RLU (relative luciferase units). **(c)** DMH1 blocked BMP4-induced Smad 1/5/8 phosphorylation in HEK293 cells. In contrast, DMH1 had no effect on **(c)** BMP4-induced p38 MAPK phosphorylation, and on **(d)** Activin A-induced Smad2 phosphorylation in HEK293 cells. **(e)** DMH1 had no effect on VEGF-induced Flk1 phosphorylation in BAECs.

Figure 5. DMH4 is a potent and selective inhibitor of VEGF signaling
(a) DMH4 disrupted both ISV and SIV formation at 1 μM. Fluorescent vascular images of DMSO-treated embryo are shown on the left of DMH4-treated embryos. **(b)** DMH4 had no effect on dorsoventral axis at 50 μM when treated from 3-hpf. **(c)** DMH4 (1 μM) blocked VEGF-induced tubular network formation in HUVECs. **(d)** DMH4 did not show significant inhibition of BMP signaling in a BMP-responsive luciferase reporter assay, but **(e, f)** it blocked VEGF-induced phosphorylation of Flk1 and AKT in BAECs.

Table 1

R2	Dorsalization (EC100, μM)	ISV disruption (EC50, μM)	Toxicity (EC100, μM)
	2.5	5	20

R2	Dorsalization (EC100, μM)	ISV disruption (EC50, μM)	Toxicity (EC100, μM)
	3	20	20
	5	50	No (>50)

R2	Dorsalization (EC100, μM)	ISV disruption (EC50, μM)	Toxicity (EC100, μM)
	1	5	20

R2	Dorsalization (EC100, μM)	ISV disruption (EC50, μM)	Toxicity (EC100, μM)
	2	2	5

R2	Dorsalization (EC100, μM)	ISV disruption (EC50, μM)	Toxicity (EC100, μM)
	No (>50)	No (>50)	No (>50)

R2	Dorsalization (EC100, µM)	ISV disruption (EC50, µM)	Toxicity (EC100, µM)
	0.2	No (>50)	No (>50)

R2	Dorsalization (EC100, μM)	ISV disruption (EC50, μM)	Toxicity (EC100, μM)
	0.1	No (>50)	25
	1	No (>50)	No (>50)
	No (>50)	1	No (>50)

R2	Dorsalization (EC100, μM)	ISV disruption (EC50, μM)	Toxicity (EC100, μM)
	No	2	5

oventral (DV) axis, the intersomitic vessel (ISV)
s are severely dorsalized. Due to significant day-
sruption, the EC50 represents the concentration
exhibit either early lethality within hours of
n. Results from at least 20 embryos per condition.

Table 2

The effects of the DM and five of the analogs on various *in vitro* kinase assays

	IC50 (nM)				
	ALK2 (BMPR-I)	**ALK5 (TGFβR-I)**	**AMPK**	**KDR (VEGFR2)**	**PDGFRβ**
DMH1	107.9	No	No	No	No
DMH2	42.8	1578.0	3527.0	2418.0	n.t.
DMH3	26.7	998.0	1940.0	2062.0	n.t.
DMH4	3558.0	No	8038.0	161.0	n.t.
DM	148.1	10,760.0	234.6	25.1	n.t.
LDN-193189	40.7	565.0	1122.0	214.7	n.t.
Staurosporine	4531.0	10,640.0	<1.0	3.29	6.14

Shown are the IC50's (concentrations causing 50% inhibition) of DM and the analogs for the *in vitro* kinase assays using the following purified human enzymes: the BMP type-I receptor activin receptor-like kinase 2 (ALK2/BMPR-I), the TGFβ type-I receptor activin receptor-like kinase 5 (ALK5/TGFβR-I), the VEGF type-2 receptor (VEGFR2/KDR), the AMP-activated protein kinase (AMPK) and the platelet-derived growth factor receptor-β (PDGFRβ). In *in vitro* kinase assays, DM was relatively nonspecific, targeting ALK2, AMPK and KDR with IC50s less than 250 nM. LDN-193189 was slightly more selective, but it still had significant effects against ALK5 and KDR. By comparison, DMH1, DMH2 and DMH3 were much more selective ALK2 inhibitors. In particular, DMH1 had no detectible activity against any of the kinases tested besides ALK2. DMH4 was a selective KDR inhibitor with modest effect on ALK2 (IC50 3.6 µM) and minimal effect on AMPK (IC50 8.0 µM). Nonspecific kinase inhibitor staurosporine was used as a control. All of the reactions were carried out in the presence of 10 µM ATP. "No," no inhibition; "n.t.," not tested.